SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
This article was originally published in The Gray Sheet
Executive Summary
SpectRx could be cash-flow neutral in 2005 if SimpleChoice diabetes management product line sales increase as expected, CFO Thomas Muller predicted during a March 31 earnings call